secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sunshine Biopharma Inc. (SBFM)
CIK:        0001402328
Form:       8-K
Filed at:   2025-04-02T23:59:59+00:00
Accession:  0001683168-25-002193
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sunshine Biopharma FY2024 revenue $34.9M (+45% YoY); net loss widens to $5.1M
-----------------------------------------------------------------------------

- Revenue $34.9M in FY2024, up 45% from $24.1M in FY2023; gross profit $10.7M.
- Net loss $5.1M vs $4.5M in FY2023; G&A expenses $16.5M, up from $13.1M.
- Completed ~$10M underwritten public offering for expansion of sales operations.
- Launched 13 new generic drugs; received Health Canada approval for oncology drug NIOPEG.
- Published PLpro inhibitor study in J. Med. Chem.; completed mouse model proof-of-concept for K1.1 mRNA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1402328/000168316825002193/0001683168-25-002193-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1402328/000168316825002193/sunshine_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-25-002193

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer